<DOC>
	<DOCNO>NCT02604784</DOCNO>
	<brief_summary>Single center , open label , non-randomized , single-arm , repeat single dose study explore efficacy , safety , Overall Response Rate ( ORR ) cisplatin , oxaliplatin doxorubicin give pressurized intraperitoneal chemotherapy ( PIPAC ) patient ( men woman ) peritoneal carcinomatosis ovarian , gastric colorectal cancer primary cancer peritoneum .</brief_summary>
	<brief_title>Study Efficacy Safety Laparoscopic Intra-abdominal Chemotherapy ( PIPAC ) Performed Patients With Peritoneal Carcinomatosis From Colorectal , Ovarian , Gastric Cancer Primary Peritoneal Tumors</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Clinical pathological confirmation peritoneal carcinomatosis gastric , colorectal ovarian cancer primary peritoneal tumor . Patients age 18 78 year . Performance status sec . ECOG â‰¤ 2 Disease progression/relapse least one line previous i.v . standard chemotherapy gastric cancer primary peritoneal tumor two line colorectal ovarian cancer . Patients peritoneal carcinomatosis ovarian , gastric colorectal cancer primary peritoneal cancer eligible cytoreductive surgery +/ HIPEC . Blood electrolyte count , liver , renal cardiopulmonary function parameter within 10 % normal range . Written informed consent . Tumor mass present CTscan order allow tumor response assessment RECISTcriteria . Extraabdominal metastatic disease , exception isolate pleural carcinomatosis . Bowel obstruction . Chemotherapy surgery within last two week prior enrollment . Severe renal impairment , myelosuppression , severe hepatic impairment , severe myocardial insufficiency , recent myocardial infarction , severe arrhythmia . Immunocompromised patient immunosuppressive medication know disease immune system . Creatinine clearance &lt; 60 ml /min . Pregnancy . Previous treatment reach maximum cumulative dose doxorubicin , daunorubicin , epirubicin , idarubicin and/or anthracyclines anthracenediones . Known allergy cisplatin platinumcontaining compound doxorubicin . Patients sexes conduct complete abstinence heterosexual relationship agree use effective clinically acceptable method ( failure rate &lt; 1 % ) study follow 6 month last treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pressurized Intra Peritoneal Air-flow Chemotherapy ( PIPAC )</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Peritoneal Carcinomatosis</keyword>
</DOC>